Literature DB >> 25416385

Mitochondrial integrity in a neonatal bovine model of right ventricular dysfunction.

Danielle R Bruns1, R Dale Brown2, Kurt R Stenmark2, Peter M Buttrick1, Lori A Walker3.   

Abstract

Right ventricular (RV) function is a key determinant of survival in patients with both RV and left ventricular (LV) failure, yet the mechanisms of RV failure are poorly understood. Recent studies suggest cardiac metabolism is altered in RV failure in pulmonary hypertension (PH). Accordingly, we assessed mitochondrial content, dynamics, and function in hearts from neonatal calves exposed to hypobaric hypoxia (HH). This model develops severe PH with concomitant RV hypertrophy, dilation, and dysfunction. After 2 wk of HH, pieces of RV and LV were obtained along with samples from age-matched controls. Comparison with control assesses the effect of hypoxia, whereas comparison between the LV and RV in HH assesses the additional impact of RV overload. Mitochondrial DNA was unchanged in HH, as was mitochondrial content as assessed by electron microscopy. Immunoblotting for electron transport chain subunits revealed a small increase in mitochondrial content in HH in both ventricles. Mitochondrial dynamics were largely unchanged. Activity of individual respiratory chain complexes was reduced (complex I) or unchanged (complex V) in HH. Key enzymes in the glycolysis pathway were upregulated in both HH ventricles, alongside upregulation of hypoxia-inducible factor-1α protein. Importantly, none of the changes in expression or activity were different between ventricles, suggesting the changes are in response to HH and not RV overload. Upregulation of glycolytic modulators without chamber-specific mitochondrial dysfunction suggests that mitochondrial capacity and activity are maintained at the onset of PH, and the early RV dysfunction in this model results from mechanisms independent of the mitochondria.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  cardiac; mitochondria; pulmonary hypertension; right ventricle

Mesh:

Substances:

Year:  2014        PMID: 25416385      PMCID: PMC4338944          DOI: 10.1152/ajplung.00270.2014

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  42 in total

1.  Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension.

Authors:  N W Morrell; S M Danilov; K B Satyan; K G Morris; K R Stenmark
Journal:  Cardiovasc Res       Date:  1997-05       Impact factor: 10.787

Review 2.  The failing heart--an engine out of fuel.

Authors:  Stefan Neubauer
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

Review 3.  The metabolic theory of pulmonary arterial hypertension.

Authors:  Roxane Paulin; Evangelos D Michelakis
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Alpha-skeletal actin messenger RNA increases in acute right ventricular hypertrophy.

Authors:  P R Bakerman; K R Stenmark; J H Fisher
Journal:  Am J Physiol       Date:  1990-04

Review 5.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

Review 6.  Mitochondrial dynamics in heart failure.

Authors:  Le Chen; A A Knowlton
Journal:  Congest Heart Fail       Date:  2011 Nov-Dec

7.  Adaptation to hypoxia alters energy metabolism in rat heart.

Authors:  W L Rumsey; B Abbott; D Bertelsen; M Mallamaci; K Hagan; D Nelson; M Erecinska
Journal:  Am J Physiol       Date:  1999-01

8.  Pressure-induced regulation of myosin expression in rodent heart.

Authors:  F Haddad; P W Bodell; K M Baldwin
Journal:  J Appl Physiol (1985)       Date:  1995-04

Review 9.  Mitochondrial dysfunction in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  10 in total

Review 1.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

2.  Band on the run: insights into right ventricular reverse remodelling.

Authors:  Robert D Brown; Mehdi A Fini; Kurt R Stenmark
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

Review 3.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

4.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Authors:  Tim Lahm; Ivor S Douglas; Stephen L Archer; Harm J Bogaard; Naomi C Chesler; Francois Haddad; Anna R Hemnes; Steven M Kawut; Jeffrey A Kline; Todd M Kolb; Stephen C Mathai; Olaf Mercier; Evangelos D Michelakis; Robert Naeije; Rubin M Tuder; Corey E Ventetuolo; Antoine Vieillard-Baron; Norbert F Voelkel; Anton Vonk-Noordegraaf; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

Review 5.  Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease.

Authors:  Sang-Bing Ong; Siavash Beikoghli Kalkhoran; Hector A Cabrera-Fuentes; Derek J Hausenloy
Journal:  Eur J Pharmacol       Date:  2015-05-16       Impact factor: 4.432

6.  Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension.

Authors:  Jose L Izquierdo-Garcia; Teresa Arias; Yeny Rojas; Victoria Garcia-Ruiz; Arnoldo Santos; Silvia Martin-Puig; Jesus Ruiz-Cabello
Journal:  Front Cardiovasc Med       Date:  2018-08-15

7.  Metabolic Response to Stress by the Immature Right Ventricle Exposed to Chronic Pressure Overload.

Authors:  Masaki Kajimoto; Muhammad Nuri; Nancy G Isern; Isabelle Robillard-Frayne; Christine Des Rosiers; Michael A Portman
Journal:  J Am Heart Assoc       Date:  2019-08-27       Impact factor: 5.501

Review 8.  PGC-1α activity and mitochondrial dysfunction in preterm infants.

Authors:  Atefeh Mohammadi; Randa Higazy; Estelle B Gauda
Journal:  Front Physiol       Date:  2022-09-26       Impact factor: 4.755

9.  Metabolic Remodeling in the Pressure-Loaded Right Ventricle: Shifts in Glucose and Fatty Acid Metabolism-A Systematic Review and Meta-Analysis.

Authors:  Anne-Marie C Koop; Guido P L Bossers; Mark-Jan Ploegstra; Quint A J Hagdorn; Rolf M F Berger; Herman H W Silljé; Beatrijs Bartelds
Journal:  J Am Heart Assoc       Date:  2019-10-28       Impact factor: 5.501

10.  Resveratrol Prevents Right Ventricle Dysfunction, Calcium Mishandling, and Energetic Failure via SIRT3 Stimulation in Pulmonary Arterial Hypertension.

Authors:  Judith Bernal-Ramírez; Christian Silva-Platas; Carlos Jerjes-Sánchez; Martín R Ramos-González; Eduardo Vázquez-Garza; Héctor Chapoy-Villanueva; Alicia Ramírez-Rivera; Ángel Zarain-Herzberg; Noemi García; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2021-06-20       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.